The compound attacks MRSA, C. diff, and several other deadly pathogens. Its discovery demonstrates the power of combining computational biology, genetic sequencing, and synthetic chemistry to study bacterial evolution.
Increasingly, hospitalized patients contract infections that evade current antibiotics including colistin, long used as a last treatment option. The discovery of a new colistin variant might make it possible to outmaneuver these pathogens.
Researchers found that the antibodies present in people who have had COVID or taken two doses of mRNA vaccine are inadequate against Omicron. But their protective ability increases significantly after a booster dose.